Trevi Therapeutics
0 followers
TRVI
Performance
About Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER) for treatment of chronic cough associated with conditions such as idiopathic pulmonary fibrosis and other interstitial lung diseases. The company highlights its investigational therapy targeting the cough reflex through central and peripheral mechanisms and has reported phase 2 trial results indicating reductions in cough frequency. Headquartered in New Haven, Connecticut, Trevi communicates its pipeline and investor information through its website and affiliated investor resources. The site also underscores its commitment to patients and ongoing research in chronic cough conditions.
Recent News
No recent news for this company.